Relevant bibliographies by topics / Rivaroxaban

Academic literature on the topic 'Rivaroxaban'

Author: Grafiati
Published: 4 June 2021
Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Rivaroxaban.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Journal articles on the topic "Rivaroxaban":

1

Petzold, Tobias, Manuela Thienel, Lisa Dannenberg, Philipp Mourikis, Carolin Helten, Aysel Ayhan, René M’Pembele, et al. "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1." Circulation Research 126, no. 4 (February 14, 2020): 486–500. http://dx.doi.org/10.1161/circresaha.119.315099.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Rationale: A reduced rate of myocardial infarction has been reported in patients with atrial fibrillation treated with FXa (factor Xa) inhibitors including rivaroxaban compared with vitamin K antagonists. At the same time, low-dose rivaroxaban has been shown to reduce mortality and atherothrombotic events in patients with coronary artery disease. Yet, the mechanisms underlying this reduction remain unknown. Objective: In this study, we hypothesized that rivaroxaban’s antithrombotic potential is linked to a hitherto unknown rivaroxaban effect that impacts on platelet reactivity and arterial thrombosis. Methods and Results: In this study, we identified FXa as potent, direct agonist of the PAR-1 (protease-activated receptor 1), leading to platelet activation and thrombus formation, which can be inhibited by rivaroxaban. We found that rivaroxaban reduced arterial thrombus stability in a mouse model of arterial thrombosis using intravital microscopy. For in vitro studies, atrial fibrillation patients on permanent rivaroxaban treatment for stroke prevention, respective controls, and patients with new-onset atrial fibrillation before and after first intake of rivaroxaban (time series analysis) were recruited. Platelet aggregation responses, as well as thrombus formation under arterial flow conditions on collagen and atherosclerotic plaque material, were attenuated by rivaroxaban. We show that rivaroxaban’s antiplatelet effect is plasma dependent but independent of thrombin and rivaroxaban’s anticoagulatory capacity. Conclusions: Here, we identified FXa as potent platelet agonist that acts through PAR-1. Therefore, rivaroxaban exerts an antiplatelet effect that together with its well-known potent anticoagulatory capacity might lead to reduced frequency of atherothrombotic events and improved outcome in patients.
2

Hawes, Emily M., Allison M. Deal, Dorothy M. Adcock, Robert Gosselin, Cheryl Jeanneret, Kenneth D. Friedman, Stephan Moll, and Suzanne J. Francart. "Performance of coagulation tests in patients on therapeutic doses of rivaroxaban." Thrombosis and Haemostasis 111, no. 06 (2014): 1133–40. http://dx.doi.org/10.1160/th13-10-0871.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
SummaryKnowledge of anticoagulation status during rivaroxaban therapy is desirable in certain clinical situations. It was the study objective to determine coagulation tests most useful for assessing rivaroxaban’s anticoagulant effect. Peak and trough blood samples from 29 patients taking rivaroxaban 20 mg daily were collected. Mass spectrometry and various coagulation assays were performed. “On-therapy range” was defined as the rivaroxaban concentrations determined by LC-MS/ MS. A “misprediction percentage” was calculated based on how often results of each coagulation assay were in the normal reference range, while the rivaroxaban concentration was in the “on-therapy” range. The on-therapy range was 8.9 – 660 ng/ml. The misprediction percentages for prothrombin time (PT) and activated partial thromboplastin time (aPTT), using multiple reagents and coagulometers, ranged from 10% – 52% and 31% – 59%, respectively. PT, aPTT and activated clotting time (ACT) were insensitive to trough rivaroxaban: 59%, 62%, and 80% of samples had a normal result, respectively. Over 95% of PT and ACT values were elevated at peak. Four different rivaroxaban calibrated anti-Xa assays had R2 values >0.98, demonstrating strong correlations with rivaroxaban drug levels. In conclusion, PT, aPTT and ACT are often normal in patients on therapeutic doses of rivaroxaban. However, PT and ACT may have clinical utility at higher drug plasma levels. Rivaroxaban calibrated anti-factor Xa assays can accurately identify low and high on-therapy rivaroxaban drug levels and, therefore, have superior utility in all clinical situations where assessment of anticoagulation status may be beneficial.This trial is registered at www.clinicaltrials.gov (#NCT01743898).
3

Jennings, Sin-Ling T., Khanh N. P. Manh, and Jusilda Bita. "Morbidly Obese Patient on Rivaroxaban Presents With Recurrent Upper Extremity Deep Vein Thrombosis: A Case Report." Journal of Pharmacy Practice 33, no. 5 (June 23, 2019): 712–19. http://dx.doi.org/10.1177/0897190019851358.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
A morbidly obese patient with history of deep vein thrombosis and pulmonary embolism was diagnosed with an acute left upper extremity deep vein thrombosis and started on rivaroxaban. Three months later, the patient returned with swelling in the right arm and was found to have a right brachial thrombosis. Anticoagulant therapy was switched to a low-molecular-weight heparin, and patient was discharged on enoxaparin along with an order to follow-up with a hematologist. Subanalyses from randomized controlled trials, pharmacokinetic/pharmacodynamic, and real-world studies suggest that rivaroxaban may be effective and safe in morbidly obese patients for primary and secondary prevention of venous thromboembolism. However, the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis does not recommend the use of direct-acting oral anticoagulants in this population. If used, drug levels should be monitored to guide the therapy. Due to the disparity in data to show efficacy and safety of rivaroxaban in morbidly obese subjects, the interpatient variability of rivaroxaban’s effects in subjects, and the lack of defined therapeutic range for rivaroxaban drug concentration, rivaroxaban should be used cautiously in this population.
4

Weiss, Luisa, Paulina Szklanna, Tadhg Prendiville, Karl Egan, Sarah Kelliher, Aine Lennon, Eugene Dillon, et al. "Comprehensive Multi-Parameter Characterisation of Circulating Extracellular Vesicles from Rivaroxaban-Treated VTE Patients Reveals Reduced Inflammation and Ameliorated Endothelial Dysfunction." Blood 138, Supplement 1 (November 5, 2021): 3210. http://dx.doi.org/10.1182/blood-2021-146131.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Abstract Venous Thromboembolism (VTE) remains a significant cause of morbidity and mortality worldwide. Rivaroxaban, a direct oral factor Xa inhibitor, mediates anti-inflammatory and cardiovascular-protective effects besides its well-established anticoagulant properties, however, these remain poorly characterized. Extracellular vesicles (EVs) are important circulating messengers regulating a myriad of biological and pathological processes and may be highly relevant to the pathophysiology of VTE as they reflect alterations in platelet and endothelial biology. However, the effects of Rivaroxaban on circulating pro-inflammatory EVs in VTE patients remain unknown. We hypothesized that rivaroxaban's anti-inflammatory properties are reflected upon differential molecular profiles of circulating EVs. Single-episode VTE patients anticoagulated with 20 mg Rivaroxaban or warfarin at a target INR of 2.0-3.0, respectively, who had commenced therapy no sooner than 3 months previously were recruited following informed written consent at the Mater Misericordiae University Hospital, Dublin, Ireland. Patient data including age, sex, BMI, prevalent risk factors and comorbidities were collected. Patients on warfarin therapy had a time in therapeutic range of at least 55% and an INR in target range at time of blood sampling. Exclusion criteria included known pro-inflammatory conditions, active malignancy, recurrent VTE, antiphospholipid syndrome, bleeding or platelet function disorders, use of anti-platelet drugs, and thrombocytopenia. To address the hypothesis, we firstly used a combination of Nanoparticle Tracking Analysis (NTA) and flow cytometry to comprehensively characterise differences in the concentration and size of small (0-200 nm) and large (200-1000 nm) circulating EVs, respectively. Statistical analysis revealed a trend towards reduced levels of circulating small and large EVs in Rivaroxaban-treated VTE patients compared with matched warfarin controls. Moreover, small and large EVs measured in the patients plasma correlated strongly and highly significantly (r=0.804, p<0.0001), indicating a concomitant decrease in both populations. As circulating EVs are considered pro-coagulant and pro-inflammatory, these results may point towards an ameliorated baseline pro-inflammatory state of VTE patients anticoagulated with Rivaroxaban. To further uncover Rivaroxaban-mediated alterations, we next compared proteomic profiles of circulating EVs. We robustly quantified over 300 vesicular proteins. Statistical analysis of the protein expression level using a student's t-test with a false discovery rate of 5% and a minimal fold change of 0.1 identified differential protein expression of a tightly regulated cluster of proteins involved in negative feedback regulation of inflammatory and coagulation pathways in Rivaroxaban-treated patients, which may in part contribute to the superior outcomes of Rivaroxaban-treated patients seen in recent clinical trials. Furthermore, we recently established that Rivaroxaban potentially ameliorates endothelial dysfunction in a cohort of non-valvular atrial fibrillation patients. Therefore, we aimed to also assess circulating markers of endothelial activation (Intercellular Adhesion Molecule 1 [ICAM-1] and Tissue Factor Pathway Inhibitor [TFPI]). Intriguingly, Rivaroxaban-treated patients exhibited an increase in plasma TFPI levels with a simultaneous decrease in soluble ICAM-1, potentially pointing towards ameliorated endothelial dysfunction in Rivaroxaban-treated VTE patients relative to warfarin. Collectively, we established that EV proteomic signatures are powerful biological sensors of Rivaroxaban's anti-inflammatory potential. Moreover, Rivaroxaban therapy may ameliorate endothelial dysfunction relative to warfarin. These findings are of translational relevance towards characterizing the anti-inflammatory and cardiovascular-protective mechanisms associated with Rivaroxaban therapy. Disclosures Kevane: Leo Pharma: Research Funding. Murphy: Bayer Pharma: Research Funding. Ni Ainle: Daiichi-Sankyo: Research Funding; Actelion: Research Funding; Leo Pharma: Research Funding; Bayer Pharma: Research Funding. Maguire: Bayer Pharma: Research Funding; Actelion: Research Funding.
5

Duggan, Sean T., Lesley J. Scott, and Greg L. Plosker. "Rivaroxaban." Drugs 69, no. 13 (September 2009): 1829–51. http://dx.doi.org/10.2165/11200890-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Duggan, Sean T. "Rivaroxaban." American Journal Cardiovascular Drugs 12, no. 1 (February 2012): 57–72. http://dx.doi.org/10.2165/11208470-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mueck, Wolfgang, Anthonie W. A. Lensing, Giancarlo Agnelli, Hervé Decousus, Paolo Prandoni, and Frank Misselwitz. "Rivaroxaban." Clinical Pharmacokinetics 50, no. 10 (October 2011): 675–86. http://dx.doi.org/10.2165/11595320-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kakar, P., T. Watson, and G. Y. H. Lip. "Rivaroxaban." Drugs of Today 43, no. 3 (2007): 129. http://dx.doi.org/10.1358/dot.2007.43.3.1067345.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rees, Sharon. "RIVAROXABAN." Journal of Prescribing Practice 3, no. 6 (June 2, 2021): 210–12. http://dx.doi.org/10.12968/jprp.2021.3.6.210.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chen, Terry, and Sum Lam. "Rivaroxaban." Cardiology in Review 17, no. 4 (July 2009): 192–97. http://dx.doi.org/10.1097/crd.0b013e3181aa2154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Rivaroxaban' for particular source types:
Journal articles Dissertations / Theses

Dissertations / Theses on the topic "Rivaroxaban":

1

Rocha, Helena Clarisse Mota Fiuza da. "Novos anticoagulantes orais." Master's thesis, [s.n.], 2015. http://hdl.handle.net/10284/5306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Projeto de Pós-Graduação/Dissertação apresentado à Universidade Fernando Pessoa como parte dos requisitos para obtenção do grau de Mestre em Ciências Farmacêuticas
Durante longos anos, os antagonistas da vitamina K e as heparinas foram os únicos anticoagulantes disponíveis. Apesar de eficazes na prevenção/tratamento das doenças tromboembólicas, apresentam numerosas limitações. No sentido de ultrapassar estas limitações, têm vindo a ser desenvolvidos novos fármacos, que ao contrário dos anteriores atuam num único fator da coagulação específico. Após vários estudos de eficácia e segurança, o dabigatrano etexilato (inibidor direto da trombina), o rivaroxabano e o apixabano (inibidores diretos do fator Xa) foram aprovados para prevenção de acidente vascular cerebral (AVC) e do tromboembolismo venoso em pacientes submetidos a artroplastia eletiva da anca ou joelho, para reduzir o risco de AVC e embolismo sistémico em pacientes com fibrilhação auricular não-valvular e também como tratamento em pacientes com trombembolismo venoso agudo. Estes novos anticoagulantes orais além de serem farmacologicamente previsíveis, não sofrem interações significativas com alimentos, nem com outros fármacos, não necessitam de monitorização laboratorial regular e são de administração oral. Os resultados dos estudos demonstraram que são pelo menos tão eficazes como a varfarina mas mais seguros, uma vez que apresentam um risco de hemorragias major inferior. No entanto, muito ainda está por explorar, sendo necessário prosseguir com as investigações nesta área, conhecendo melhor os efeitos a longo prazo e garantindo uma melhor eficácia e segurança para os pacientes.
For many years, vitamin K antagonists and heparins were the only available anticoagulants. Although effective in the prevention/treatment of thromboembolic diseases, they have numerous limitations. In order to overcome these drawbacks, new drugs that act on a single specific coagulation factor have been developed. After several studies on efficacy and safety, dabigatran etexilate (direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors) have been approved for prevention of stroke and venous thromboembolism in patients undergoing elective arthroplasty of hip or knee, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and in the treatment of patients with acute venous thromboembolism. These new oral anticoagulants are pharmacologically predictable, do not suffer from interaction with other drugs or with food, do not require regular laboratory monitoring and are orally active. The results of the studies showed that are at least as effective as warfarin but safer, since the risk of major bleeding is shorter. However, much remains to be explored, it is necessary to proceed with the investigations in this area, ensuring better efficacy and safety for patients.
2

Brüggemann, Stefan [Verfasser]. "Die Wirkung von Rivaroxaban auf die Frakturheilung der Ratte / Stefan Brüggemann." Kiel : Universitätsbibliothek Kiel, 2017. http://d-nb.info/1127044125/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Coleman, Craig I., Jan Beyer-Westendorf, Thomas J. Bunz, Charles E. Mahan, and Alex C. Spyropoulos. "Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism." Sage, 2018. https://tud.qucosa.de/id/qucosa%3A35470.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Postthrombotic syndrome (PTS) is a frequent complication of venous thromboembolism (VTE). Using MarketScan claims data from January 2012 to June 2015, we identified adults with a primary diagnosis code for VTE during a hospitalization/emergency department visit, ≥6 months of insurance coverage prior to the index event and newly started on rivaroxaban or warfarin within 30 days of the index VTE. Patients with <4-month follow-up postindex event or a claim for any anticoagulant during 6-month baseline period were excluded. Differences in baseline characteristics between rivaroxaban and warfarin users were adjusted for using inverse probability of treatment weights based on propensity scores. Patients were followed for the development of PTS starting 3 months after the index VTE. Cox regression was performed and reported as hazard ratios with 95% confidence intervals (CIs). In total, 10 463 rivaroxaban and 26 494 warfarin users were followed for a mean of 16 ± 9 (range, 4-39) months. Duration of anticoagulation was similar between cohorts (median = 6 months). Rivaroxaban was associated with a 23% (95% CI: 16-30) reduced hazard of PTS versus warfarin. Rivaroxaban was associated with a significant risk reduction in symptoms of PTS compared to warfarin in patients with VTE treated in routine practice.
4

DIMATTEO, CLAUDIA. "Studio di associazione tra fattori genetici e livelli plasmatici in pazienti trattati con NAO: Dabigatran, Rivaroxaban e Apixaban." Doctoral thesis, Università di Foggia, 2016. http://hdl.handle.net/11369/338843.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Introduzione: gli anticoagulanti orali svolgono un importante ruolo nel ridurre complicanze e mortalità associate ai disturbi tromboembolici. Il Warfarin, un antagonista della vitamina K (AVK), ha rappresentato per 50 anni l’unico farmaco disponibile ed efficace per la profilassi di eventi tromboembolici, i cui limiti sono dati da un monitoraggio dell’INR, da interazioni alimentari e farmacologiche. Tali limiti sono stati superati con i nuovi anticoagulanti orali (NAO), che si somministrano in dosi fisse, non necessitano di monitoraggio continuo, hanno una rapida insorgenza d’azione, un buon profilo di sicurezza, una farmacodinamica ed una farmacocinetica prevedibile, poche interazioni con cibo e farmaci, e sono utilizzati nella terapia anticoagulante orale di quei pazienti con patologie come fibrillazione atriale, cardiopatie dilatative, valvulopatie, malattie tromboemboliche e protesi valvolari cardiache. Si tratta del Dabigatran, inibitore diretto della trombina (fattore IIa), e del Rivaroxaban e Apixaban, inibitori del fattore Xa. È stata riportata una variabilità inter-individuale nelle concentrazioni di farmaco ritrovate nel sangue; in particolare i geni ABCB1 e CES1 esercitano un effetto importante nel metabolismo degli anticoagulanti e varianti alleliche in questi due loci giocano un ruolo determinante sulla suscettibilità del farmaco. Obiettivi: analizzare i polimorfismi su geni coinvolti nel processo metabolico del Dabigatran, Rivaroxaban e Apixaban, in particolare sul gene ABCB1 che codifica per un trasportatore della glicoproteina P (pompa di efflusso ATP-dipendente) per tutti e tre i farmaci e sul gene CES1 che è un enzima metabolizzante carbossilesterasi 1, che interviene nella trasformazione del dabigatran etexilato in forma attiva. Inoltre, determinazione della concentrazione plasmatica dei 3 farmaci prima e dopo assunzione dello stesso. Materiali e Metodi: In una coorte di 92 pazienti in terapia con i dabigatran, 51 con rivaroxaban e71 con apixaban, abbiamo esaminato, attraverso sequenziamento diretto, le varianti geniche del gene ABCB1(rs4148738) per tutti i farmaci e le varianti geniche del gene CES1 (rs8192935 e rs2244613) per i pazienti in dabigatran e determinato la concentrazione plasmatica di valle e di picco dei farmaci stessi, attraverso la tecnica combinata HPLC-spettrometria di massa. Risultati e Conclusioni: Tra i 92 pazienti che assumono dabigatran (età media: 72.0 anni) analizzati, nessuna variabile clinico o genotipo è stata associata con una differenza significativa nelle concentrazioni di picco di dabigatran. Per quanto riguarda le concentrazioni di valle, oltre alla clearance della creatinina, e il sesso è stata rilevata una significativa associazione con i rs8192935 CES1 SNP (p = 0,023). I livelli plasmatici medi aggiustati erano più elevati tra i pazienti con il genotipo CC (86,3 ng / dl) rispetto a quelli che portano l’allele T (62,1 ng / dl). Nessun effetto significativo è stato rilevato per i rs4148738 ABCB1 SNP. Nel caso del Rivaroxaban per entrambe le dosi, non è stato trovato nessun effetto dello SNP ABCB1 sui livelli plasmatici. Per l’Apixaban, invece, è stata rilevata un’associazione con la dose di 10 mg, in particolare una significativa associazione con lo SPN di ABCB1 (p=0,048). Abstract in English Background: the oral anticoagulants play an important role in reducing complications and mortality associated with thromboembolic disorders. Warfarin, a vitamin K antagonist (VKA), represented for 50 years the only drug available and effective for the prophylaxis of thromboembolic events, but it presents the limits, in particular it needs a monitoring of INR, interaction of food and drug. These limits have been exceeded with the new oral anticoagulants (NAO), which are administered in fixed doses, do not require continuous monitoring, they have a rapid onset of action, a good safety profile, pharmacodynamics and pharmacokinetics predictable, few interactions with food and drugs, and are used in the oral anticoagulation therapy for patients with diseases such as atrial fibrillation, dilated heart disease, valvular disease, thromboembolic disease and heart valve prostheses. They are the Dabigatran, direct inhibitor of thrombin (factor IIa), and the rivaroxaban and apixaban, factor Xa inhibitors. It was found an inter-individual variability in drug concentrations found in the blood; especially the ABCB1 and CES1 genes exert an important effect in the metabolism of anticoagulants and allelic variants in these two loci play a decisive role on the susceptibility of the drug. Objectives: to analyze the polymorphisms of genes involved in the metabolic process of dabigatran, rivaroxaban and apixaban, in particular on the ABCB1 gene encoding a transporter P-glycoprotein (ATP-dependent efflux pump) for all three drugs and CES1 gene that is an enzyme carboxylesterase 1, which is involved in the transformation of dabigatran etexilate in active form. Furthermore, we have determined the plasma concentration of 3 drugs before and after intake of the same. Patients/Methods: In a cohort of 92 patients treated with dabigatran, 51 with rivaroxaban and 71 with apixaban, we have examined by direct sequencing, gene variants of the ABCB1 (rs4148738 gene) for all drugs and genetic variants of CES1 gene (rs8192935 and rs2244613) for patients on dabigatran and we have determined the plasma concentration of trough and peak of the drugs, by the combined technique HPLC-mass spectrometry . Results and Conclusion: Among the 92 patients treated with dabigatran (mean age: 72.0 years) analyzed, no clinical variable or genotype was associated with a significant difference in peak concentrations of dabigatran. As for trough concentrations, in addition to creatinine clearance and sex it is found a significant association with rs8192935 SNP CES1 (p=0.023) . The adjusted average plasma levels were higher among patients with the CC genotype (86.3 ng/dl) than those who carry the T allele (62.1 ng/dl). No significant effect was observed for the ABCB1 SNP rs4148738. In the case of rivaroxaban for both doses, it was not found any of the ABCB1 SNP effect on plasma levels. For the apixaban, instead, an association has been detected with the dose of 10 mg, in particular a significant association with the SPN of the ABCB1 (p = 0.048).
5

Mrotzek, Silvia Jasmin [Verfasser]. "Effekte von Rivaroxaban und Enoxaparin auf die osteogene Differenzierung humaner mesenchymaler Stromazellen in vitro / Silvia Jasmin Mrotzek." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2017. http://d-nb.info/1137502193/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Harrington, Amanda Rose. "Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for the Prevention of Stroke Prophylaxis in Atrial Fibrillation." Thesis, The University of Arizona, 2012. http://hdl.handle.net/10150/268612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Objective: The primary objective of this study was to estimate the long-term cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the United States using new anticoagulant therapies - dabigatran 150 mg, apixaban 5 mg, and rivaroxaban 20 mg - as well as the standard treatment, warfarin. Methods: A Markov decision-analysis model was constructed using data from clinical trials that evaluated the new oral anticoagulants relative to warfarin (apixaban 5 mg & ARISTOTLE, dabigatran 150 mg & RE-LY, and rivaroxaban 20 mg & ROCKET-AF) to compare the lifetime cost and quality-adjusted life expectancy. The Markov model target population was a hypothetical cohort of 70-year old patients with nonvalvular atrial fibrillation, an increased risk for stroke (CHADS₂ ≥ 1, or equivalent), a renal creatinine clearance (CrCl) of 50 or above, and no contraindication to anticoagulant therapy. Using pair-wise comparisons of each therapy, analyses were conducted to evaluate incremental cost-effectiveness ratios (ICERs), net monetary benefits (NMBs), lifetime costs, life-years, and quality-adjusted life-years (QALYs). Results: In the base case, warfarin had the lowest cost of $71,857 (95% confidence interval [CI]: $68,730, $77,452), followed by rivaroxaban 20 mg ($74,023; 95% CI: $70,943, $77,307), dabigatran 150 mg ($78,584; 95% CI: $75,277, $81,968), and apixaban 5 mg ($81,180; 95% CI: $78,642, $83,756). Apixaban 5 mg also yielded the highest QALY estimate, 8.63 (95% CI: 8.52, 8.72), followed by dabigatran 150 mg (8.55; 95% CI: 8.43, 8.67), rivaroxaban 20 mg (8.42; 95% CI: 8.31, 8.54), and warfarin (8.17; 95% CI: 8.1, 8.24). In a Monte Carlo probabilistic sensitivity analysis, apixaban 5 mg, dabigatran 150 mg, rivaroxaban 20 mg, and warfarin were cost effective in 45%, 37%, 19%, 0%, respectively, of the simulations using a willingness-to pay threshold of $50,000 per QALY gained. From the one-way sensitivity analyses, new anticoagulant (apixaban 5 mg, dabigatran 150 mg, rivaroxaban 20 mg) costs and probabilities associated with intracranial hemorrhage and stroke for patients receiving rivaroxaban 20 mg were identified as significant influential variables impacting model results. Conclusion: In patients with NVAF and an increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg may all be cost-effective alternatives to warfarin depending on pricing in the United States and neurologic events for rivaroxaban 20 mg.
7

Wingert, Nathalie Ribeiro. "Desenvolvimento e validação de métodos analíticos e estudos de estabilidade da rivaroxabana." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2015. http://hdl.handle.net/10183/149500.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
A análise de fármacos é fundamental nas diversas fases do desenvolvimento farmacêutico, tais como estudos de formulação, estabilidade e controle de qualidade do produto. A rivaroxabana (RIV) é um anticoagulante de uso oral indicado para prevenção da formação de coágulos venosos. A literatura pesquisada apresenta poucos relatos de determinação quantitativa e de estudos de estabilidade do fármaco em comprimidos. E ainda nenhum método analítico em compêndios oficiais Diante do exposto, o objetivo deste trabalho foi desenvolver e validar métodos analíticos para determinação qualitativa e quantitativa da RIV por cromatografia líquida de alta eficiência com detecção por UV e de ultra eficiência com detecção por espectrometria de massas (CLAE-UV e CLUE-EM) e eletroforese capilar (EC). Os resultados encontrados foram adequados conforme o preconizado nos guias oficiais nacionais e internacionais. Foi avaliada também a viabilidade da técnica de eletroforese capilar em microchip para análise de RIV. Através de método desenvolvido por CLAE foi realizado estudo de cinética de degradação e posterior avaliação do potencial tóxico in vitro das amostras de degradação forçada da RIV. A identificação de três produtos de degradação majoritários da RIV, formados a partir de estresse ácido, alcalino e fotolítico, foi realizada por CLUE-EM/EM, possibilitando a proposição da estrutura molecular de cada produto de degradação. O potencial tóxico da RIV antes e depois da exposição à degradação forçada foi avaliado através dos métodos in vitro MTT, Vermelho Neutro, Ensaio Cometa e DNA de baixo peso molecular. Não foram encontrados sinais de dano ao DNA celular, contudo, amostras de RIV expostas ao meio alcalino apresentaram maior redução da viabilidade celular. O trabalho avaliou ainda o perfil de dissolução da RIV em comprimidos baseado nos dados de absorção in vitro conforme modelagem in silico dos dados, estabelecendo uma correlação linear entre a fração absorvida e fração dissolvida. As diferentes metodologias e técnicas desenvolvidas e aplicadas nesse trabalho contribuem para o desenvolvimento do controle de qualidade farmacêutico na direção de ensaios mais confiáveis que garantam a segurança e eficácia de medicamentos.
Drug analysis is critical at various stages of pharmaceutical development, such as formulation studies, stability and quality control products. Rivaroxaban (RIV) is an oral anticoagulant indicated for prevention of thromboembolism. Literature contains few reports of quantitative determination and drug stability studies of RIV on pharmaceutical formulation. Analytical method for RIV quality control are not evaluable on official guides yet. This research work aimed to develop and validate analytical methods for qualitative and quantitative determination of RIV by high and ultra performance liquid chromatography with UV detection mass spectrometry detection (HPLC -UV and UPLC-MS) and capillary electrophoresis (CE). The results were adequate as recommended in national and international official guides. Reliability of RIV analysis by microchip capillary electrophoresis was also assessed. Through the method developed by HPLC degradation kinetic studies were performed, zero order kinetic has better description of RIV degradation behaviour. RIV toxic potential before and after exposure to forced degradation was assessed by in vitro methods of MTT, Neutral Red, Comet Assay, and Low Molecular Weight DNA. There were no signals of DNA damage however, RIV samples exposed to alkaline medium showed increased reduction in cell viability. Identification of RIV degradation products formed after exposure to acid and alkaline media and UVC radiation was performed by UPLC-MS / MS. It was possible to elucidate molecular structures of three major degradation products. This study also assessed the dissolution profile of RIV tablets based on in vitro absorption data, a linear point-to-point correlation was found for fraction absorbed and dissolved. Different methodologies and techniques developed and applied in this work can contribute to the development of pharmaceutical quality towards more reliable tests to ensure safety and efficacy of medicines.
8

TOSCANO, Paulo Martins. "Perfil molecular em genes cyp3a4 e cyp2j2: um caminho para a farmacogenética do Rivaroxaban em uma população do Norte do Brasil." Universidade Federal do Pará, 2014. http://repositorio.ufpa.br/jspui/handle/2011/8911.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Submitted by Hellen Luz (hellencrisluz@gmail.com) on 2017-07-24T16:22:21Z No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_PerfilMolecularGenes.pdf: 1048037 bytes, checksum: d0479df3122ed434a7a26c2cbc4534bf (MD5)
Approved for entry into archive by Irvana Coutinho (irvana@ufpa.br) on 2017-07-25T13:09:26Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_PerfilMolecularGenes.pdf: 1048037 bytes, checksum: d0479df3122ed434a7a26c2cbc4534bf (MD5)
Made available in DSpace on 2017-07-25T13:09:26Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_PerfilMolecularGenes.pdf: 1048037 bytes, checksum: d0479df3122ed434a7a26c2cbc4534bf (MD5) Previous issue date: 2014-01-23
Nos últimos anos, novos anticoagulantes têm sido desenvolvidos com o objetivo de minimizar as dificuldades encontradas no manejo clínico das drogas convencionais, porém não existem dados publicados sobre a sua farmacogenética. Diante da hipótese de que os polimorfismos relacionados à sua metabolização possam ser fonte de variabilidade genética, o presente estudo objetiva realizar inferências de epidemiologia molecular dos polimorfismos nos genes CyP3a4 (rs2246709) e CyP2j2 (rs890293), relacionados ao metabolismo do Rivaroxaban, um novo inibidor direto do fator Xa. São analisadas 136 amostras de indivíduos saudáveis de uma população do Norte do Brasil que apresenta um elevado grau de mistura interétnica. Para alcançar o objetivo farmacogenético foi realizada, em paralelo, análise de ancestralidade genômica nos indivíduos investigados. Os resultados demonstraram diferenças significativas entre os genótipos do CyP3a4 observados no estudo, quando comparados a todas as populações ancestrais para o polimorfismo 99365719 a>G (P<0,05). a população miscigenada do Norte do Brasil, portanto, apresentou diferença na distribuição das frequências genotípicas em relação aos grupos ancestrais, formadores de nossa população. O mesmo achado não é observado para polimorfismo do gene do CyP2j2. Destaca-se que o polimorfismo no gene do CyP3a4, na amostra investigada, sofre influência da contribuição étnica européia individual. Considerando, a elevada miscigenação que caracteriza a população local e o avanço da Farmacogenômica na medicina atual, os dados podem contribuir para a melhor compreensão da farmacogenética do novo anticoagulante.
In recent years, new anticoagulants have been developed with the purpose of minimizing the difficulties encountered in the clinical management of conventional dru- gs, but there are no published data on its pharmacogenetics. Considering the hypothe- sis that polymorphisms related to its metabolism may be the source of genetic variability, this study aims to make inferences on molecular epidemiology of polymorphisms in CyP3a4 (rs2246709) and CyP2j2 (rs890293) genes related to the metabolism of Rivaroxaban, a new direct factor Xa inhibitor. 136 samples from healthy individuals in a population of northern Brazil with a high degree of inter-ethnic mix, so as to guarantee that the pharmacogenetic goal was achieved, have been subjected to a parallel analysis of genomic ancestry for the individuals investigated. The results sho- wed significant differences among genotypes for CyP3a4 observed in the study com- pared to all ancestral populations for a polymorphism 99,365,719 a> G ( P < 0.05). The mixed population of northern Brazil, therefore, showed differences in the distribution of genotype frequencies in relation to ancestral groups, forming our population. The same finding was not observed for the CyP2j2 gene polymorphism. It is noteworthy that the polymorphism in the CyP3a4 gene in the investigated sample is influenced by indivi- dual ethnic European contribution. Considering the high miscegenation featuring local people, and the advancement of Pharmacogenomics in current medicine, such data can contribute to a better understanding of the pharmacogenetics of that new anticoagulant.
9

Klee, Thorben [Verfasser]. "Die murine polymikrobielle Sepsis als Modell der disseminierten intravasalen Gerinnung und deren Beeinflussung durch die Medikamente Rivaroxaban und Clopidogrel / Thorben Klee." Greifswald : Universitätsbibliothek Greifswald, 2017. http://d-nb.info/1136294635/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ikesaka, Rick. "The Risk of Upper Extremity Deep Vein Thrombosis and Primary Thromboprophylaxis with Low Dose Rivaroxaban in Oncology Patients with Central Venous Catheters." Thesis, Université d'Ottawa / University of Ottawa, 2021. http://hdl.handle.net/10393/41954.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Venous thromboembolism (VTE) is a common disorder which causes significant morbidity and mortality. Upper extremity deep vein thrombosis(UEDVT) is a relatively understudied subtype of VTE which is commonly associated with central venous catheters, cancer, and thrombophilia. The goal of this project was to better characterize the risk of UEDVT and to design and execute a pilot study that will demonstrate the efficacy of a strategy preventing the occurrence of VTE in a high-risk population for UEDVT. This M.Sc project, was conducted in three parts. Chapter 1 of the thesis outlines a systematic review of the literature which assessed the risk of VTE in UEDVT patients by search for and including data from studies with patients with prospectively enrolled symptomatic UEDVT. Chapter 2 describes the development and final protocol of the TRIM-Line pilot study, a randomized open-label study comparing 90 days of rivaroxaban 10mg po daily against the current standard of care (observation) in patients with active cancer and central venous catheters, two known risk factors for VTE. Finally in Chapter 3 the TRIM-Line study was executed as a pilot trial involving The Ottawa Hospital and the Juravinski Cancer Centre located in Hamilton. The study was conducted from March 2019 until February 2020. 105 patients underwent randomization at the two Canadian centres. The study met its prespecified feasibility endpoint average enrolment rate of 7.5 per month (95% CI:4.56, 10.44) at the coordinating Ottawa Hospital site and 2.0 per month (95% CI:0.87, 3.13) for the Juravinski Cancer Centre site. The randomized controlled trial met its enrollment targets and demonstrated that a full scale randomized controlled trial on the topic of prevention of cancer associated venous thromboembolism is feasible.
More sources

Books on the topic "Rivaroxaban":

1

Smetak, Norbert. Praxisleitfaden Rivaroxaban. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-40703-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Smetak, Norbert. Praxisleitfaden Rivaroxaban: Moderne Antikoagulationstherapie in der Internistischen Praxis. Springer London, Limited, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Smetak, Norbert. Praxisleitfaden Rivaroxaban: Moderne Antikoagulationstherapie in der Internistischen Praxis. Springer Berlin / Heidelberg, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Rivaroxaban":

1

Smetak, Norbert. "Paradigmenwechsel in der oralen Antikoagulation." In Praxisleitfaden Rivaroxaban, 5–12. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-40703-1_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Smetak, Norbert. "Allgemeine Fragen zur Anwendung von Rivaroxaban." In Praxisleitfaden Rivaroxaban, 13–38. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-40703-1_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Smetak, Norbert. "Rivaroxaban für die gerinnungshemmende Therapie bei Vorhofflimmern." In Praxisleitfaden Rivaroxaban, 39–48. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-40703-1_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Smetak, Norbert. "Rivaroxaban für die Therapie der tiefen Beinvenenthrombose und Lungenembolie." In Praxisleitfaden Rivaroxaban, 49–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-40703-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Smetak, Norbert. "EINSTEIN Studienprogramm zur Behandlung der tiefen Venenthrombose." In Praxisleitfaden Rivaroxaban, 59–62. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-40703-1_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ferrandis, Raquel. "New Drugs for Thromboprophylaxis: Apixaban, Dabigatran, Rivaroxaban." In Thromboembolism in Orthopedic Surgery, 67–79. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-4336-9_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mousa, Shaker A. "Oral Direct Factor Xa Inhibitors, with Special Emphasis on Rivaroxaban." In Anticoagulants, Antiplatelets, and Thrombolytics, 181–201. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-803-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Ji, and Jason Crawford. "Rivaroxaban (Xarelto): A Factor Xa Inhibitor for the Treatment of Thrombotic Events." In Modern Drug Synthesis, 191–205. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.1002/9780470768594.ch14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Shuen, Ng Wei, Hou Weihan, and Choo Jun An Jerry. "Predicting In Vivo Drug–Drug Interactions Between Rivaroxaban and Tyrosine Kinase Inhibitors Arising from Mechanism-Based Inactivation of Cytochrome P450 3A4." In IRC-SET 2021, 403–14. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-9869-9_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Noguez, Jaime H., and James C. Ritchie. "Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS)." In Methods in Molecular Biology, 21–27. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3252-8_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Rivaroxaban":

1

Stammler, Romain, Paul Legendre, Patrice Cacoub, Philippe Blanche, Jean Charles Piette, and Nathalie Costedoat-Chalumeau. "P7 Rivaroxaban may trigger catastrophic antiphospholipid syndrome." In 12th European Lupus Meeting. Lupus Foundation of America, 2020. http://dx.doi.org/10.1136/lupus-2020-eurolupus.56.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chopra, M., and E. Cristan. "Rivaroxaban Induced Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4953.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Villgran, V. D., S. Patel, and B. E. DiSilvio. "An Unusual Case of Eosinophilic Pleural Effusion and Rivaroxaban Hypersensitivity." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Helmkamp, K., L. Gonzalez, R. M. Davis, and D. Taneja. "A Rare and Fatal Case of Rivaroxaban Induced Acute Liver Failure." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4838.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

van den Heuvel, Robert. "'No’ to routine use of rivaroxaban in outpatients with COVID-19." In AHA Scientific Sessions 2022, edited by Marc Bonaca. Baarn, the Netherlands: Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/fc908f27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lipardi, C., C. G. Elliott, L. Haskell, A. Spyropoulos, G. Raskob, J. Xu, W. Lu, T. Spiro, and E. S. Barnathan. "Risk of Severe Bleeding with Rivaroxaban in Medically Ill Patients with Bronchiectasis." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5712.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Stankovic, P., C. Frommelt, S. Hammel, R. Georgiew, J. Wittlinger, D. Obradovic, S. Hoch, N. Dagres, and T. Wilhelm. "Shorter hospital stays in epistaxis patients taking Rivaroxaban and Apixaban vs. Phenprocoumon." In Abstract- und Posterband – 90. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Digitalisierung in der HNO-Heilkunde. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1686754.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Stankovic, P., C. Frommelt, S. Hammel, R. Georgiew, J. Wittlinger, D. Obradovic, S. Hoch, N. Dagres, and T. Wilhelm. "Kürzere Verweildauer bei Epistaxis-Patienten unter Rivaroxaban und Apixaban im Vergleich zu Phenprocoumon." In Abstract- und Posterband – 90. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Digitalisierung in der HNO-Heilkunde. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1686692.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Svet, Mark, and Rachel Giles. "New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?" In 71st ACC Scientific Session, edited by Marc Bonaca. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/1563f707.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vigneron, Clara, Alexandre Vivot, Matthieu Jamme, Aude Gibelin, Guillaume Briend, Jean Pastré, Benjamin Planquette, Guy Meyer, and Olivier Sanchez. "Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3654.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Rivaroxaban":

1

Zheng, Xu-ya, Lin Zhang, and Junfeng Zhang. Bleeding outcomes associated with dabigatran and rivaroxaban used in patients with non-valvular atrial fibrillation：a meta-analysis of random control trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Purba, Abdul, Saraswati Gumilang, Dhihintia Jiwangga, Nurina Hasanatuludhhiyah, and Maarten Postma. Cost and clinical outcomes in the use of new oral anticoagulants versus warfarin in deep vein thrombosis: A systematic review protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2022. http://dx.doi.org/10.37766/inplasy2022.12.0106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Review question / Objective: What are the benefits of using new oral anticoagulants compared to warfarin in terms of efficacy, bleeding, and cost among people with deep vein thrombosis? This study aimed to compare the effectiveness, bleeding incidence, and cost between NOAC and warfarin in DVT patients. Condition being studied: The patient confirmed DVT with the results of the Wells' score and D-dimer test stating "possible DVT" and followed by an ultrasound examination which stated "DVT positive". Patients are taking oral anticoagulants to treat DVT or to prevent a recurrence. Oral anticoagulants consist of apixaban, rivaroxaban, edoxaban, dabigatran, and warfarin.
3

Rivaroxaban plus aspirin may reduce heart attack and strokes in people with peripheral arterial disease, but with an added risk of bleeding. National Institute for Health Research, February 2018. http://dx.doi.org/10.3310/signal-000554.

Full text
APA, Harvard, Vancouver, ISO, and other styles

To the bibliography